GRCL - Utang jangka cendhak marang modal Gracell Biotechnologies Inc.

The primary threats to Gracell Biotechnologies (GRCL) remain the high cost of biologics logistics and the uncertainty surrounding clinical trial outcomes. Nevertheless, the strategic talent of the management team and the transparency of their research enabled the platform to be acquired by AstraZeneca. This chart of the debt-to-equity ratio on GURU.Markets shows 0.05, while the company adheres to environmental waste disposal standards.

This ratio measures the proportion of short-term liabilities within the equity structure, determining liquidity risk and the efficiency of financial leverage. By analyzing the history of short-term loans to equity, an investor assesses the company's resilience to rising rates, which is critical for Gracell Biotechnologies (GRCL) when scaling FasTCAR, where strong pricing power and unique therapy speed should ensure the coverage of current debts.